1. Home
  2. ATCH vs EVAX Comparison

ATCH vs EVAX Comparison

Compare ATCH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AtlasClear Holdings Inc.

ATCH

AtlasClear Holdings Inc.

HOLD

Current Price

$0.18

Market Cap

34.9M

Sector

N/A

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$3.52

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCH
EVAX
Founded
2022
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.9M
31.9M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
ATCH
EVAX
Price
$0.18
$3.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
1.5M
31.7K
Earning Date
05-15-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.20
52 Week High
$1.92
$12.15

Technical Indicators

Market Signals
Indicator
ATCH
EVAX
Relative Strength Index (RSI) 28.23 46.95
Support Level $0.17 $2.45
Resistance Level $0.24 $3.62
Average True Range (ATR) 0.01 0.41
MACD -0.00 -0.01
Stochastic Oscillator 2.21 30.00

Price Performance

Historical Comparison
ATCH
EVAX

About ATCH AtlasClear Holdings Inc.

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: